1. Search Result
Search Result
Results for "

Peptide R

" in MedChemExpress (MCE) Product Catalog:

164

Inhibitors & Agonists

21

Biochemical Assay Reagents

112

Peptides

2

Inhibitory Antibodies

1

Natural
Products

8

Recombinant Proteins

1

Isotope-Labeled Compounds

4

Antibodies

1

Click Chemistry

9

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P4111A

    CXCR Cancer
    Peptide R (TFA) is a synthetic and specific CXCR4 antagonist. Peptide R (TFA) shows outstanding capacities to remodel the tumor stroma. Peptide R (TFA) can be used for solid tumor (glioblastoma, etc.) research .
    Peptide R TFA
  • HY-P0133B
    (Arg)9 acetate
    1 Publications Verification

    Nona-L-arginine acetate; Peptide R9 acetate

    Ser/Thr Protease Neurological Disease
    (Arg)9 (Nona-L-arginine) acetate is a cell-penetrating peptide (CPP) made up of 9 arginine residues. (Arg)9 acetate has neuroprotective property, exhibits neuroprotective activity with an IC50 of 0.78 μM in the glutamic acid model .
    (Arg)9 acetate
  • HY-P0133A
    (Arg)9 TFA
    1 Publications Verification

    Nona-L-arginine TFA; Peptide R9 TFA

    Ser/Thr Protease Neurological Disease
    (Arg)9 (Nona-L-arginine) TFA is a cell-penetrating peptide (CPP) made up of 9 arginine residues. (Arg)9 TFA has neuroprotective property, exhibits neuroprotective activity with an IC50 of 0.78 μM in the glutamic acid model .
    (Arg)9 TFA
  • HY-P10723

    Interleukin Related Inflammation/Immunology
    IL-23R inhibitor peptide-1 (comp 475) is an interleukin-23 receptor inhibitor, with an IC50 of 0.0069 μM .
    IL-23R inhibitor peptide-1
  • HY-P4111

    CXCR Cancer
    Peptide R, a cyclic peptide, is a specific CXCR4 antagonist. Peptide R shows outstanding capacities to profoundly remodel the tumor stroma. Peptide R has the potential for tumor research .
    Peptide R
  • HY-P11011

    Pep R54; CXCR4 antagonist Peptide 19

    CXCR Cancer
    Peptide R54 (Pep R54; CXCR4 antagonist peptide 19) is an antagonistic peptide targeting CXCR4 with significant anticancer activity. Peptide R54 inhibits CXCR4-dependent cell migration, epithelial-mesenchymal transition, and lung metastasis development, with better serum stability and higher CXCR4 affinity than the lead compound (IC50=20 nM). Peptide R54 synergizes with anti-PD-1 therapy to exert anti-tumor activity in vivo, enhances granzyme activity, and reduces infiltration of Foxp3 cells. Peptide R54 can be used in the study of colon cancer, ovarian cancer, and melanoma .
    Peptide R54
  • HY-P10973

    CXCR ERK Cancer
    Peptide R analogue 10 (compound 10) is an analog of the CXCR4 antagonist peptide Peptide R (HY-P4111) with stronger antagonistic potency, specificity and plasma stability. Peptide R analogue 10 can inhibit CXCL12-mediated cell migration, ERK phosphorylation and CXCR4 internalization. Peptide R analogue 10 can be used in the study of CXCR4 overexpressing leukemia and colon cancer .
    Peptide R analogue 10
  • HY-P0133

    Nona-L-arginine; Peptide R9

    Ser/Thr Protease Neurological Disease
    (Arg)9 (Nona-L-arginine) is a cell-penetrating peptide (CPP) made up of 9 arginine residues, which is an inhibitor of serine endoprotease Furin. (Arg)9 has neuroprotective property, exhibits neuroprotective activity with an IC50 of 0.78 μM in the glutamic acid model .
    (Arg) 9
  • HY-P10510

    Biochemical Assay Reagents Others
    R5 peptide is one of the repeating peptide sequences that form the protein diatom in Cylindrotheca fusiformis. R5 peptide can be used as a template for the synthesis of Pd (palladium) nanoparticles (NPs). R5 peptide forms complexes with metal ions through the amine groups in its sequence, and the self-assembled structure of the peptide provides a confined spatial environment for the reduction of metal ions and the nucleation of nanoparticles. R5 peptide can be used in the research of biomimetic nanomaterials .
    R5 peptide
  • HY-P3918

    p38 MAPK Others
    EGF-R (661-681) T669 Peptide is a MAPK substrate that can used to measure MAPK catalytic activity .
    EGF-R (661-681) T669 Peptide
  • HY-172673

    GCGR Metabolic Disease
    GLP-1R agonist 31 (Compound 1) is an amorphous glucagon-like peptide-1 receptor (GLP-1R) agonist .
    GLP-1R agonist 31
  • HY-168585

    GLP Receptor Metabolic Disease
    GLP-1R agonist 26 (compound 1) is a glucagon-like peptide-1 receptor (GLP-1R) agonist with an EC50 of <10 nM .
    GLP-1R agonist 26
  • HY-147625

    GLP Receptor Metabolic Disease
    GLP-1R agonist 12 (Compound 123) is an agonist of glucagon-like peptide-1 receptors (GLP-1R). GLP-1R agonist 12 can be used for diabetes research .
    GLP-1R agonist 12
  • HY-P3291
    Dapiglutide
    1 Publications Verification

    ZP7570

    GCGR Metabolic Disease
    Dapiglutide (ZP7570) is a long-acting glucagon-like peptide-1 receptor 1R (GLP-1R)/Glucagon-like peptide-2 receptor (GLP-2R) dual agonist. Dapiglutide alleviates intestinal dysfunction in a mouse short bowel model and has anti-obesity effects .
    Dapiglutide
  • HY-116819A

    GCGR Metabolic Disease
    VU0453379 hydrochloride is a highly selective and central nervous system (CNS) penetrant positive allosteric modulator (PAM) of glucagon-like peptide-1R (GLP-1R) with an EC50 of 1.3 μM .
    VU0453379 hydrochloride
  • HY-116819

    GCGR Metabolic Disease
    VU0453379 is a highly selective and central nervous system (CNS) penetrant positive allosteric modulator (PAM) of glucagon-like peptide-1R (GLP-1R) with an EC50 of 1.3 μM .
    VU0453379
  • HY-112679

    GCGR Others
    GLP-1 receptor agonist 2 is a glucagon-like peptide-1 receptor (GLP-1R) agonist.
    GLP-1 receptor agonist 2
  • HY-P3506
    Retatrutide
    2 Publications Verification

    LY3437943

    GCGR GLP Receptor Metabolic Disease
    Retatrutide (LY3437943) is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide binds human GCGR, GIPR, and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide can be used for the research of obesity .
    Retatrutide
  • HY-P3506B

    LY3437943 acetate

    GCGR GLP Receptor Metabolic Disease
    Retatrutide (LY3437943) acetate is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide acetate inhibits human GCGR, GIPR, and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide acetate can be used for the research of obesity .
    Retatrutide acetate
  • HY-P3506A
    Retatrutide TFA
    2 Publications Verification

    LY3437943 TFA

    GLP Receptor GCGR Metabolic Disease
    Retatrutide (LY3437943) TFA is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide TFA binds human GCGR, GIPR, and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide TFA can be used for the research of obesity .
    Retatrutide TFA
  • HY-144035

    GCGR Cancer
    GLP-1R agonist 4 is a potent agonist of GLP-1R. Glucagon-like peptide-1 (GLP-1) is an intestinal hypoglycemic hormone secreted by L-cells in the lower gastrointestinal tract. GLP-1R agonist 4 has the potential for the research of diabetes (extracted from patent WO2019239319A1, compound 96) .
    GLP-1R agonist 4
  • HY-162435

    GLP Receptor Metabolic Disease
    GLP-1R agonist 20 (Compound I-132) is an agonist for glucagon-like peptide-1 receptor (GLP-1 receptor), with EC50 of 0.0162 nM .
    GLP-1R agonist 20
  • HY-162436

    GLP Receptor Metabolic Disease
    GLP-1R agonist 21 (Compound I-134) is an agonist for glucagon-like peptide-1 receptor (GLP-1 receptor), with EC50 of 0.0104 nM .
    GLP-1R agonist 21
  • HY-162437

    GLP Receptor Metabolic Disease
    GLP-1R agonist 22 (Compound I-135) is an agonist for glucagon-like peptide-1 receptor (GLP-1 receptor), with EC50 of 0.0165 nM .
    GLP-1R agonist 22
  • HY-144034

    GCGR Metabolic Disease
    GLP-1R agonist 3 is a potent agonist of GLP-1R. GLP-1R agonist 3 is a thickened imidazole derivative compound. Glucagon-like peptide-1 (GLP-1) is an intestinal hypoglycemic hormone secreted by L-cells in the lower gastrointestinal tract. GLP-1R agonist 3 has the potential for the research of diabetes (extracted from patent WO2021197464A1, compound 1) .
    GLP-1R agonist 3
  • HY-144033

    GCGR Metabolic Disease
    GLP-1R agonist 1 is a potent agonist of GLP-1R. GLP-1R agonist 1 is a thickened imidazole derivative compound. Glucagon-like peptide-1 (GLP-1) is an intestinal hypoglycemic hormone secreted by L-cells in the lower gastrointestinal tract. GLP-1R agonist 1 has the potential for the research of diabetes (extracted from patent WO2021197464A1, compound 4) .
    GLP-1R agonist 1
  • HY-112185
    Orforglipron
    1 Publications Verification

    LY3502970; GLP-1 receptor agonist 1

    GCGR Metabolic Disease
    Orforglipron (LY3502970) (Compound 67) is an orally active agonist for Glucagon-like peptide-1 receptor (GLP-1R), which exhibits potency in ameliorates the type 2 diabete .
    Orforglipron
  • HY-125824
    Danuglipron
    3 Publications Verification

    PF-06882961

    GCGR Metabolic Disease
    Danuglipron (PF-06882961) is an orally active glucagon-like peptide-1 receptor (GLP-1R) agonist. Danuglipron has the potential for type 2 diabetes research .
    Danuglipron
  • HY-P10116

    APTscr-9R

    STAT Others
    APTSTAT3-9R, scrambled (APTscr-9R) is a control peptide that forms a structure similar to that of APTSTAT3-9R but possesses a scrambled sequence in the target-binding region .
    APTSTAT3-9R, scrambled
  • HY-P5329

    NADPH Oxidase Others
    r8-Gly-Noxa A BH3 is a biological active peptide. (This cell permeable peptide is derived from the BH3 domain (a death domain) of Noxa A, amino acid residues 17 to 36. Eight D-Arginine residues and a Glycine linker residue are added to the amino terminal of the peptide.)
    r8-Gly-Noxa A BH3
  • HY-142162

    GCGR Metabolic Disease
    LSN3318839 is an orally active positive modulator of the glucagon-like peptide-1 receptor (GLP-1R). LSN3318839 can increase the secretion of insulin and has the effect of lowering blood sugar .
    LSN3318839
  • HY-125824A

    PF-06882961 tromethamine

    GCGR Metabolic Disease
    Danuglipron (PF-06882961) tromethamine is an orally active glucagon-like peptide-1 receptor (GLP-1R) agonist. Danuglipron tromethamine has the potential for type 2 diabetes research .
    Danuglipron tromethamine
  • HY-176770

    GLP Receptor Metabolic Disease
    GLP-1R agonist 34 (Compound 1) is an orally active small molecule glucagon-like peptide-1 receptor (GLP-1R) agonist. GLP-1R agonist 34 promotes insulin secretion, inhibits glucagon release, and delays gastric emptying, thereby effectively lowering blood glucose levels. GLP-1R agonist 34 is promising for research of metabolic diseases, including type 2 diabetes, obesity, and non-alcoholic steatohepatitis (NASH) .
    GLP-1R agonist 34
  • HY-171850

    GLP Receptor Metabolic Disease Inflammation/Immunology
    GLP-1R modulator-1 (Compound 384) is an orally active, potent selective glucagon-like peptide-1 receptor (GLP-1R) agonist. GLP-1R modulator-1 activates G-protein coupled signaling, elevates intracellular cAMP levels, promotes insulin secretion, delays gastric emptying and suppresses appetite. GLP-1R modulator-1 is promising for research of type 2 diabetes, obesity, and non-alcoholic steatohepatitis (NASH) .
    GLP-1R modulator-1
  • HY-142162A

    GCGR Metabolic Disease
    (S,R)-LSN3318839 is the stereoisomer of LSN3318839 (HY-142162). LSN3318839 is an orally active positive modulator of the glucagon-like peptide-1 receptor (GLP-1R). LSN3318839 can increase the secretion of insulin and has the effect of lowering blood sugar .
    (S,R)-LSN3318839
  • HY-172276A

    Liposome Cancer
    DSPE-PEG2000-R8 is a PEG compound which composed of DSPE and a cell-penetrating peptide (R8). pDSPE-PEG2000-R8 can be used for drug delivery .
    DSPE-PEG2000-Mal-Cys-RRRRRRRR
  • HY-172276

    Liposome Cancer
    DSPE-PEG1000-R8 is a PEG compound which composed of DSPE and a cell-penetrating peptide (R8). pDSPE-PEG1000-R8 can be used for drug delivery .
    DSPE-PEG1000-Mal-Cys-RRRRRRRR
  • HY-172276C

    Liposome Cancer
    DSPE-PEG3400-R8 is a PEG compound which composed of DSPE and a cell-penetrating peptide (R8). pDSPE-PEG3400-R8 can be used for drug delivery .
    DSPE-PEG3400-Mal-Cys-RRRRRRRR
  • HY-172276B

    Liposome Cancer
    DSPE-PEG5000-R8 is a PEG compound which composed of DSPE and a cell-penetrating peptide (R8). pDSPE-PEG5000-R8 can be used for drug delivery .
    DSPE-PEG5000-Mal-Cys-RRRRRRRR
  • HY-P5438

    Btk c-Kit FAK FLT3 Insulin Receptor Others
    Srctide is a biological active peptide. (This is a peptide substrate for many protein kinases, such as Blk, BTK, cKit, EPHA1, EPHB2, EPHB3, ERBB4, FAK, Flt3, IGF-1R, ITK, Lck, MET, MUSK, Ret, Src, TIE2, TrkB, VEGF-R1 (Flt-1) and VEGF-R2 (KDR).)
    Srctide
  • HY-143312A

    GLP Receptor Metabolic Disease
    V-0219 hydrochloride (Compound 9) is an orally active, positive allosteric modulator (PAM) of the glucagon-like peptide-1 receptor (GLP-1R). V-0219 hydrochloride can be used for obesity-associated diabetes research .
    V-0219 hydrochloride
  • HY-143312

    GLP Receptor Metabolic Disease
    V-0219 (Compound 9) is an orally active, positive allosteric modulator (PAM) of the glucagon-like peptide-1 receptor (GLP-1R). V-0219 can be used for obesity-associated diabetes research .
    V-0219
  • HY-172277B

    Liposome Neurological Disease
    DSPE-PEG5000-R9 is a PEG compound which composed of DSPE and a poly-arginine-9 peptide (R9). DSPE-PEG5000-R9 can be used for drug delivery .
    DSPE-PEG5000-R9
  • HY-172277A

    Liposome Neurological Disease
    DSPE-PEG2000-R9 is a PEG compound which composed of DSPE and a poly-arginine-9 peptide (R9). DSPE-PEG2000-R9 can be used for drug delivery .
    DSPE-PEG2000-R9
  • HY-172277C

    Liposome Neurological Disease
    DSPE-PEG3400-R9 is a PEG compound which composed of DSPE and a poly-arginine-9 peptide (R9). DSPE-PEG3400-R9 can be used for drug delivery .
    DSPE-PEG3400-R9
  • HY-172277

    Liposome Neurological Disease
    DSPE-PEG1000-R9 is a PEG compound which composed of DSPE and a poly-arginine-9 peptide (R9). DSPE-PEG1000-R9 can be used for drug delivery .
    DSPE-PEG1000-R9
  • HY-109022A

    (3R,5R,6S)-MK-8031; (3R,5R,6S)-AGN-241689

    CGRP Receptor Neurological Disease
    (3R,5R,6S)-Atogepant ((3R,5R,6S)-MK-8031) is the enantiomer of Atogepant (HY-109022). Atogepant is a calcitonin gene-related peptide receptor (CGRP) antagonist. Atogepant can be used for researching migraine.
    (3R,5R,6S)-Atogepant
  • HY-W591317

    (R)-NODAG

    Radionuclide-Drug Conjugates (RDCs) Cancer
    (R)-NODAGA-tris(t-Bu ester) ((R)-NODAG) is a NODAGA derivative. (R)-NODAGA-tris(t-Bu ester) can be used to label peptides, antibodies, etc., and subsequently radiolabeled for PET imaging .
    (R)-NODAGA-tris(t-Bu ester)
  • HY-101116
    GLP-1R Antagonist 1
    3 Publications Verification

    GCGR Metabolic Disease
    GLP-1R Antagonist 1 (compound 5d) is an orally active, CNS penetrant and non-competitive antagonist of glucagon-like peptide 1 receptor (GLP-1R), with an IC50 of 650 nM .
    GLP-1R Antagonist 1
  • HY-P991511

    PACAP Receptor Neurological Disease
    ALD1910 is a humanized monoclonal antibody against PACAP38 and PACAP27. ALD1910 blocks PACAP signaling through the pituitary adenylate cyclase-activating peptide type I receptor (PAC1-R), vasoactive intestinal peptide receptor 1 (VPAC1-R), and VPAC2-R. ALD1910 recognizes a nonlinear epitope within PACAP and blocks its binding to the cell surface. ALD1910 can be used for the study of PACAP-mediated migraine .
    ALD1910

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: